Get the Stockscreener App
11.82
1.75%
-0.21
After Hours:
12.07
0.25
+2.12%
Arcturus Therapeutics Holdings Inc stock is traded at $11.82, with a volume of 322.03K.
It is down -1.75% in the last 24 hours and down -7.80% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$12.03
Open:
$12.47
24h Volume:
322.03K
Relative Volume:
0.78
Market Cap:
$320.56M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-10.19
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-2.72%
1M Performance:
-7.80%
6M Performance:
-32.50%
1Y Performance:
-69.23%
1-Day Range:
$11.70
$12.50
1-Week Range:
$11.70
$13.00
52-Week Range:
$8.04
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
11.82 | 329.52M | 157.75M | -29.73M | -21.00M | -1.16 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
When the Price of (ARCT) Talks, People Listen - news.stocktradersdaily.com
Scotiabank Initiates Coverage on Arcturus Therapeutics (ARCT) | - GuruFocus
Arcturus Therapeutics (ARCT) Receives Positive Outlook with Potential Upside | ARCT Stock News - GuruFocus
Scotiabank Initiates Arcturus Therapeutics at Outperform - marketscreener.com
Man Group plc Sells 4,168 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics’ SWOT analysis: mRNA innovator’s stock faces pivotal year - Investing.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Northern Trust Corp Has $4.35 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $45.00 - Defense World
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics - MSN
FY2025 EPS Estimates for ARCT Raised by Cantor Fitzgerald - The AM Reporter
Leerink Partnrs Analysts Raise Earnings Estimates for ARCT - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
William Blair Brokers Boost Earnings Estimates for ARCT - Defense World
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - Defense World
Arcturus Therapeutics (ARCT): Wells Fargo Maintains Rating, Lowe - GuruFocus
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT - GuruFocus
Arcturus Therapeutics (ARCT) Set for Potential Upside with Citi's Confidence | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $4.11, revenue fell short of estimates - Investing.com Nigeria
Canaccord Genuity Maintains Buy Rating on Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews - Benzinga
Arcturus Therapeutics (ARCT) Price Target Revised by Canaccord | - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... - Yahoo Finance
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Reports Q1 2025 Financial Update - TipRanks
Arcturus Therapeutics (ARCT) Sees Strong Progress with Pipeline Programs - GuruFocus
Earnings call transcript: Arcturus Therapeutics Q1 2025 sees revenue drop, stock rises - Investing.com
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcturus Therapeutics (ARCT) Surpasses Q1 Revenue Expectations | - GuruFocus
ARCTURUS THERAPEUTICS Earnings Results: $ARCT Reports Quarterly Earnings - Nasdaq
Arcturus Therapeutics stock jumps 7% despite Q1 loss By Investing.com - Investing.com Canada
Arcturus Therapeutics stock jumps 7% despite Q1 loss - Investing.com Australia
Arcturus Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress - Business Wire
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Dimensional Fund Advisors LP - Defense World
Arcturus Therapeutics (ARCT) to Release Quarterly Earnings on Monday - Defense World
Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result - Yahoo Finance
MetLife Investment Management LLC Has $283,000 Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Barclays PLC Sells 7,333 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline - Yahoo Finance
Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41% - simplywall.st
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):